| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| Referral date | 01 July 2010 |
| Topic area |
|
| Description |
Scoped within Batch 12 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | Jeremy Powell |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in July 2011, the appraisal of Afatinib for the treatment of locally advanced or metastatic non small cell lung cancer was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 July 2011 |
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of afatinib within its licensed indication for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib as part of our 22nd wave work programme. The Institute has been informed by the manufacturer that it is not expecting to receive a separate marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being. This indication is now planned to be part of the regulatory submission of afatinib for NSCLC, locally advanced and/or metastatic with EGFR mutation positive. |
| 3 December 2010 |
Following on from information received from the manufacturer, dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual